Kaken Pharmaceutical : Reference Data of Consolidated Financial Results for 1st Quarter of Fiscal 2023

Consolidated Financial Result for 1st Quarter of Fiscal 2023

(Reference Data of Consolidated Financial Results)

August 4, 2023

KAKEN PHARMACEUTICAL CO., LTD.

Corporate Communications

Tel: [phone]

Fax: [phone]

Email: [e-mail]

1. Summary of Consolidated Financial Statements for 1st Quarter of Fiscal 2023

(amounts are rounded down to the nearest million Yen)

	FY2022	FY2022	FY2023	Change		Plan	Change
	1Q	1Q			FY2023
		Amount	%	Amount	%
Net sales	18,197	72,984	18,150	(47)	99.7%	73,100	116	100.2%
Operating profit	4,056	7,998	3,293	(762)	81.2%	7,600	(398)	95.0%
Ratio of net sales	22.3%	11.0%	18.1%			10.4%
Ordinary profit	4,332	8,727	3,488	(843)	80.5%	8,000	(727)	91.7%
Ratio of net sales	23.8%	12.0%	19.2%			10.9%
Profit	2,907	5,440	2,510	(397)	86.3%	6,700	1,260	123.2%
Ratio of net sales	16.0%	7.5%	13.8%			9.2%
Comprehensive income	3,014	5,475	3,810	796	126.4%
R&D Expense	2,030	15,789	2,600	570	128.1%	15,100	(689)	95.6%

2. Sales of Main Pharmaceuticals and Medical Devices (non-consolidated)

(amounts are rounded down to the nearest million Yen)

	FY2022	FY2022	FY2023	Change	Plan	Change
	1Q	1Q	(%)	FY2023	(%)
Onychomycosis treatment	4,813	17,985	4,667	97.0%	17,700	98.4%
Clenafin
Anti-osteoarthritis agent	4,448	17,062	4,535	102.0%	18,000	105.5%
Artz
Post-operativeanti-adhesive	2,006	7,790	1,735	86.5%	7,300	93.7%
Seprafilm
Wound-healing agent	706	2,759	671	95.1%	2,700	97.9%
Fiblast
Primary axillary
hyperhydrosis treatment	413	1,257	687	166.2%	1,900	151.2%
Ecclock
Periodontal regenerative agent	226	891	231	102.3%	900	101.0%
Regroth
Lumber disc herniation treatment	104	392	91	88.0%	400	102.0%
Hernicore
Generic products (total)	2,108	8,201	2,013	95.5%	7,900	96.3%

2 KAKEN PHARMACEUTICAL CO., LTD.

3. Products under Development

As of August 4, 2023

Development	Planned	Development	Remarks
Code	Indication	Stage (*)
KAR	Head lice	P III	In-licensed from Arbor Pharmaceuticals, LLC.
Product name in the US: Sklice®
KP-001	Refractory vascular	P III	Development project succeeded from
(ART-001)	malformations	ARTham Therapeutics Inc.
	Primary palmoplantar		Additional indication of Ecclock, which has
BBI-4000	P I	been approved for primary axillary
hyperhidrosis
		hyperhidrosis treatment
KP-483	Solid tumors	P I	In-house discovered product
(Immuno-oncology)
NM26-2198	Atopic dermatitis	P I	Co-development with Numab Therapeutics AG
KP-910	Peripheral neuropathic	P I	In-house discovered product
pain
Seladelpar	Primary biliary	P I	In-licensed from CymaBay Therapeutics, Inc.
cholangitis
Tildacerfont	Congenital adrenal	P I	In-licensed from Spruce Biosciences, Inc.
hyperplasia
	(*) The development stage includes the preparation period for clinical trials.

3 KAKEN PHARMACEUTICAL CO., LTD.